What is the long-term trend for Anterix's indefinite-lived research and development assets?

Over 5 years (2021 to 2026), Anterix's indefinite-lived research and development assets has grown at a 20.5% compound annual growth rate (CAGR), from $122.12M to $310.71M.

Anterix ATEX Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF

Heartflow, Inc. Common StockHTFL

$15.41M-25.5%

PhotronicsPLAB

$3.9M+43.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.19M-50.8%

Tarsus Pharmaceuticals, Inc.TARS

$7.96M-63.4%

Lantheus HoldingsLNTH

$6.19M-79.2%

BlackSky TechnologyBKSY

$8.38M-29.4%

Other financials

Income statement

See full

Revenue$2.0M+41.0%

Gross profit$608.0K+81.5%

Operating income$19.8M—

Net income$18.5M—

EPS (diluted)$0.98—

Balance sheet

See full

Cash & equivalents$98.5M+108%

Total debt$4.4M-18.0%

Total equity$262.3M+67.5%

Total assets$465.2M+39.7%

Cash flow

See full

Operating cash flow$15.5M+194%

CapEx$22.0K-52.2%

Free cash flow$15.5M+193%

Valuation

See full

Market cap$1.5B+190%

Enterprise value$1.4B+196%

P/E16.5×—

P/S230.1×+145×

Profitability

See full

Gross margin-105.3%—

Operating margin1,444.9%—

Net margin1,394.2%—

FCF margin-486.7%-1,481pp

Returns & leverage

See full

Return on equity43.3%—

Debt / equity0×0.0×

Current ratio3.3×+1.1×

Where this comes from

Reported directly by Anterix in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Anterix’s 10-K, filed June 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anterix's indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anterix's indefinite-lived research and development assets?: Anterix (ATEX) reported indefinite-lived research and development assets of $310.71M in Q1 2026.
How has Anterix's indefinite-lived research and development assets changed year-over-year?: Anterix's indefinite-lived research and development assets increased by 35.7% year-over-year, from $228.98M to $310.71M.
What is the long-term trend for Anterix's indefinite-lived research and development assets?: Over 5 years (2021 to 2026), Anterix's indefinite-lived research and development assets has grown at a 20.5% compound annual growth rate (CAGR), from $122.12M to $310.71M.